NetworkNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Launches Medicinal Cannabis Division

July 24, 2018 10:12:19

PreveCeutical Medical (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) this morning announced the launch of a medicinal cannabis division, advancing PreveCeutical’s vision of becoming a global preventive healthcare company. The cannabis division’s responsibilities include bringing various high-quality, medicinal cannabis-based products to market and managing the company’s nasal delivery Sol-gel research program as well as any resulting formulations. The cannabis division’s products will include transdermal patches, topical creams, capsules and other methods of administering medicinal cannabis. “The opening of the cannabis division at this crucial moment is very exciting and continues to move the company in an important direction. With Canada’s upcoming legalization of recreational cannabis on October 17, 2018, and the reduction of stigma surrounding cannabis products, PreveCeutical sees a potential void in the medicinal cannabis sector as many companies begin to move to recreational market to accommodate demand. This market shift will provide PreveCeutical with the opportunity to focus on the healthcare sector and supply the increasing demand for effective and tailored cannabis-based therapies,” PreveCeutical Medical chairman, president and CEO Stephen Van Deventer stated in the news release.

To view the full press release, visit http://nnw.fm/3qXh4

About PreveCeutical Medical Inc.

PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Program; Nature Identical™ peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). PreveCeutical sells CELLB9®, an Immune System Booster. CELLB9® is an oral solution containing polarized and potentiated essential minerals extracted from a novel peptide obtained from Caribbean Blue Scorpion venom. This product is available on the company’s website. For more information about PreveCeutical, please visit www.PreveCeutical.com

More from NetworkNewsBreaks

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com